Adam J. Mulkern
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adam J. Mulkern has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Craig MacLean
Department of Biology, University of Oxford, UK
2 shared publications - Jörg Vogel
University of Würzburg
2 shared publications - Lars Barquist
Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz Centre for Infection Research (HZI)
2 shared publications - Linda Popella
Institute of Molecular Infection Biology, University of Würzburg, Würzburg, Germany
2 shared publications - Marco Galardini
Institute for Molecular Bacteriology, TWINCORE Centre for Experimental and Clinical Infection Research, a joint venture between the Hannover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany
2 shared publications Svetlana Ðurica-Mitić
Institute of Molecular Infection Biology, University of Würzburg, Würzburg, Germany
2 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8262
A systematic identification of resistance determinants to antisense antibiotics suggests adaptation strategies dependent on the delivery peptide
The rise of antimicrobial resistance (AMR) among human pathogens is a serious threat to global health, demanding novel treatment strategies. Antibiotics based on programmable antisense oligomers (asobiotics) offer an attractive solution, as their specificity can be quickly updated to target resistant bacteria. To understand the genetic architecture of resistance to asobiotics, we used laboratory evolution assays to identify mutations that decrease susceptibility to antisense peptide nucleic acids (PNAs) in four major gram-negative pathogens: Escherichia coli , Klebsiella pneumoniae , Salmonella enterica , and Pseudomonas aeruginosa . Reduced susceptibility depended on the cell-penetrating peptide (CPP) conjugated to the PNA, with reduced uptake emerging as a common adaptation only against the (KFF) 3 -K CPP. Accordingly, sbmA was consistently mutated across all species treated with (KFF) 3 -K-conjugated PNAs. We further identified mutations related to translation, peptide transport, and the cell envelope, generating new hypotheses on the cellular response to CPP-PNA conjugates. By contrast, for (RXR) 4 XB- acpP we observed only a modest resistance increase, driven by mutations in the PNA binding site that could be readily bypassed by changing the PNA sequence. These findings show that CPP identity strongly determines robustness against resistance evolution, and that laboratory evolution can illuminate the mechanisms of action of asobiotics.
- 12 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8262
Open AccessA systematic identification of resistance determinants to antisense antibiotics suggests adaptation strategies dependent on the delivery peptide
The rise of antimicrobial resistance (AMR) among human pathogens is a serious threat to global health, demanding novel treatment strategies. Antibiotics based on programmable antisense oligomers (asobiotics) offer an attractive solution, as their specificity can be quickly updated to target resistant bacteria. To understand the genetic architecture of resistance to asobiotics, we used laboratory evolution assays to identify mutations that decrease susceptibility to antisense peptide nucleic acids (PNAs) in four major gram-negative pathogens: Escherichia coli , Klebsiella pneumoniae , Salmonella enterica , and Pseudomonas aeruginosa . Reduced susceptibility depended on the cell-penetrating peptide (CPP) conjugated to the PNA, with reduced uptake emerging as a common adaptation only against the (KFF) 3 -K CPP. Accordingly, sbmA was consistently mutated across all species treated with (KFF) 3 -K-conjugated PNAs. We further identified mutations related to translation, peptide transport, and the cell envelope, generating new hypotheses on the cellular response to CPP-PNA conjugates. By contrast, for (RXR) 4 XB- acpP we observed only a modest resistance increase, driven by mutations in the PNA binding site that could be readily bypassed by changing the PNA sequence. These findings show that CPP identity strongly determines robustness against resistance evolution, and that laboratory evolution can illuminate the mechanisms of action of asobiotics.
- Open Access
DNA-damaging combination treatments impose genotype-specific constraints on hypermutator evolvability
Bacterial hypermutator strains drive rapid evolution of antibiotic resistance in chronic infections. Inspired by cancer therapy approaches that exploit synthetic lethality by targeting DNA repair deficiencies in hypermutator tumours, we tested whether pairing a conventional antibiotic with a secondary DNA-damaging agent could constrain hypermutator evolution in bacteria. Using high-throughput experimental evolution of Escherichia coli repair-deficient strains, we evolved populations under carbapenem selection in combination with ciprofloxacin or mitomycin C. Strains lacking oxidative damage repair, double-strand break repair, or transcription-coupled repair showed significantly reduced evolvability, particularly under constant antibiotic pressure and increasing genotoxic stress. However, mismatch repair (MMR) hypermutators, the predominant clinical genotype, did not show reduced evolvability under these combination treatments. This is consistent with pathway orthogonality: MMR does not repair the structural DNA lesions induced by ciprofloxacin or mitomycin C, and the elevated mutation supply of MMR-deficient strains may allow rapid adaptation despite background DNA damage. Our findings demonstrate that combination strategies can constrain the evolvability of specific repair-deficient genotypes in vitro , but success requires matching DNA damage type to specific repair vulnerabilities. This work establishes proof of principle for genotype-directed antimicrobial strategies that exploit DNA repair vulnerabilities to constrain hypermutator evolution. Significance: This work demonstrates that combining DNA-damaging agents with antibiotics can constrain resistance evolution in specific hypermutator genotypes, but not others. These findings establish that evolution-informed antimicrobial strategies must be genotype-specific, opening new paths for precision approaches to delay or prevent the evolution of antibiotic resistance by exploiting DNA repair vulnerabilities.
Open AccessDNA-damaging combination treatments impose genotype-specific constraints on hypermutator evolvability
Bacterial hypermutator strains drive rapid evolution of antibiotic resistance in chronic infections. Inspired by cancer therapy approaches that exploit synthetic lethality by targeting DNA repair deficiencies in hypermutator tumours, we tested whether pairing a conventional antibiotic with a secondary DNA-damaging agent could constrain hypermutator evolution in bacteria. Using high-throughput experimental evolution of Escherichia coli repair-deficient strains, we evolved populations under carbapenem selection in combination with ciprofloxacin or mitomycin C. Strains lacking oxidative damage repair, double-strand break repair, or transcription-coupled repair showed significantly reduced evolvability, particularly under constant antibiotic pressure and increasing genotoxic stress. However, mismatch repair (MMR) hypermutators, the predominant clinical genotype, did not show reduced evolvability under these combination treatments. This is consistent with pathway orthogonality: MMR does not repair the structural DNA lesions induced by ciprofloxacin or mitomycin C, and the elevated mutation supply of MMR-deficient strains may allow rapid adaptation despite background DNA damage. Our findings demonstrate that combination strategies can constrain the evolvability of specific repair-deficient genotypes in vitro , but success requires matching DNA damage type to specific repair vulnerabilities. This work establishes proof of principle for genotype-directed antimicrobial strategies that exploit DNA repair vulnerabilities to constrain hypermutator evolution. Significance: This work demonstrates that combining DNA-damaging agents with antibiotics can constrain resistance evolution in specific hypermutator genotypes, but not others. These findings establish that evolution-informed antimicrobial strategies must be genotype-specific, opening new paths for precision approaches to delay or prevent the evolution of antibiotic resistance by exploiting DNA repair vulnerabilities.
- Open Access
- 14 January 2026
- Published by Oxford University Press (OUP) in The ISME Journal
- Vol. 20 (1)
Eco-evolutionary responses to plasmid-dependent phage constrain the spread of multidrug-resistance plasmids
Phage therapy offers an alternative to antibiotics for treating multidrug-resistant infections. Plasmid-dependent phages (PDPs) are promising therapeutics as they can kill targeted pathogens and prevent the spread of plasmid-encoded antibiotic resistance genes. However, the evolutionary trajectories of multidrug-resistance (MDR) plasmids under the selective pressure of PDPs remain poorly understood, particularly in eco-evolutionary contexts that remain permissive to plasmid conjugation. We experimentally evolved populations of Escherichia coli carrying the MDR plasmid RP4 in the presence of the plasmid-dependent phage PRD1 under conditions where the benefits of conjugation were either strong or weak. When opportunities for conjugation were rare, PRD1 only transiently suppressed the conjugative plasmid population due to the rapid evolution of phage-resistant plasmids lacking conjugative ability. Increasing ecological opportunities for conjugation enhanced plasmid suppression and delayed the evolution of phage-resistant plasmids. PRD1 resistance was associated with plasmid loss and reduced conjugative ability, though this trade-off was complex because resistance mutations caused heterogeneous effects on pilus production and conjugation. Mutations and insertion sequence (IS)-mediated inactivation in conjugation genes generated a spectrum of resistance phenotypes, from partial (trbB, trbL) to complete (virB4/trbE) resistance. Bioinformatic analysis of publicly available IncP plasmids revealed frequent truncations of the VirB4/TrbE protein, suggesting that plasmid-dependent phages may represent an important selective pressure shaping plasmid evolution in natural populations. Our results demonstrate an evolutionary trade-off between conjugative ability and phage resistance that plasmids cannot easily circumvent. Targeting multidrug-resistance plasmids with PDPs is likely to drive loss of conjugation, limiting the transfer of antibiotic resistance genes in microbial communities.
- 14 January 2026
- Published by Oxford University Press (OUP) in The ISME Journal
- Vol. 20 (1)
Open AccessEco-evolutionary responses to plasmid-dependent phage constrain the spread of multidrug-resistance plasmids
Phage therapy offers an alternative to antibiotics for treating multidrug-resistant infections. Plasmid-dependent phages (PDPs) are promising therapeutics as they can kill targeted pathogens and prevent the spread of plasmid-encoded antibiotic resistance genes. However, the evolutionary trajectories of multidrug-resistance (MDR) plasmids under the selective pressure of PDPs remain poorly understood, particularly in eco-evolutionary contexts that remain permissive to plasmid conjugation. We experimentally evolved populations of Escherichia coli carrying the MDR plasmid RP4 in the presence of the plasmid-dependent phage PRD1 under conditions where the benefits of conjugation were either strong or weak. When opportunities for conjugation were rare, PRD1 only transiently suppressed the conjugative plasmid population due to the rapid evolution of phage-resistant plasmids lacking conjugative ability. Increasing ecological opportunities for conjugation enhanced plasmid suppression and delayed the evolution of phage-resistant plasmids. PRD1 resistance was associated with plasmid loss and reduced conjugative ability, though this trade-off was complex because resistance mutations caused heterogeneous effects on pilus production and conjugation. Mutations and insertion sequence (IS)-mediated inactivation in conjugation genes generated a spectrum of resistance phenotypes, from partial (trbB, trbL) to complete (virB4/trbE) resistance. Bioinformatic analysis of publicly available IncP plasmids revealed frequent truncations of the VirB4/TrbE protein, suggesting that plasmid-dependent phages may represent an important selective pressure shaping plasmid evolution in natural populations. Our results demonstrate an evolutionary trade-off between conjugative ability and phage resistance that plasmids cannot easily circumvent. Targeting multidrug-resistance plasmids with PDPs is likely to drive loss of conjugation, limiting the transfer of antibiotic resistance genes in microbial communities.
- Open Access
A systematic identification of resistance determinants to antisense antibiotics suggests adaptation strategies dependent on the delivery peptide
The rise of antimicrobial resistance (AMR) among human pathogenic microbes is a serious threat to global health, calling for the development of novel treatment strategies. Antibiotics based on programmable antisense oligomers (asobiotics) offer an attractive solution to the “arms-race”, as their specificity can be quickly updated and tailored to target resistant bacteria. In order to understand the genetic architecture of resistance to asobiotics, we employed laboratory evolution assays to identify mutations that decrease susceptibility to antisense peptide nucleic acid (PNA) against four major gram-negative pathogens: Escherichia coli, Klebsiella pneumoniae, Salmonella enterica , and Pseudomonas aeruginosa . We observed that the reduction in susceptibility upon asobiotics treatment was dependent on the specific cell penetrating peptide (CPP) being conjugated to the PNAs, suggesting that reduced uptake is a common adaptation strategy only against the (KFF) 3 -K CPP. We in fact observed that sbmA was frequently mutated in all tested species when treated with (KFF) 3 -K conjugated PNAs. We further identified mutations related to translation, peptide transport and cell envelope, which provide new hypotheses on cellular response to CPP-PNAs conjugates. Furthermore, for (RXR) 4 XB- acpP we observed a modest increase in resistance only when mutations in the PNA binding site were induced, which could easily be bypassed by changing the PNA sequence. These findings indicate that the specific identity of the CPP used plays a key role in determining its robustness against the evolution of resistance, and that laboratory evolution can illuminate the remaining gaps in our knowledge on the mechanisms of action of asobiotics.
Open AccessA systematic identification of resistance determinants to antisense antibiotics suggests adaptation strategies dependent on the delivery peptide
The rise of antimicrobial resistance (AMR) among human pathogenic microbes is a serious threat to global health, calling for the development of novel treatment strategies. Antibiotics based on programmable antisense oligomers (asobiotics) offer an attractive solution to the “arms-race”, as their specificity can be quickly updated and tailored to target resistant bacteria. In order to understand the genetic architecture of resistance to asobiotics, we employed laboratory evolution assays to identify mutations that decrease susceptibility to antisense peptide nucleic acid (PNA) against four major gram-negative pathogens: Escherichia coli, Klebsiella pneumoniae, Salmonella enterica , and Pseudomonas aeruginosa . We observed that the reduction in susceptibility upon asobiotics treatment was dependent on the specific cell penetrating peptide (CPP) being conjugated to the PNAs, suggesting that reduced uptake is a common adaptation strategy only against the (KFF) 3 -K CPP. We in fact observed that sbmA was frequently mutated in all tested species when treated with (KFF) 3 -K conjugated PNAs. We further identified mutations related to translation, peptide transport and cell envelope, which provide new hypotheses on cellular response to CPP-PNAs conjugates. Furthermore, for (RXR) 4 XB- acpP we observed a modest increase in resistance only when mutations in the PNA binding site were induced, which could easily be bypassed by changing the PNA sequence. These findings indicate that the specific identity of the CPP used plays a key role in determining its robustness against the evolution of resistance, and that laboratory evolution can illuminate the remaining gaps in our knowledge on the mechanisms of action of asobiotics.
- Open Access
- 29 August 2022
- Published by Springer Nature in npj Biofilms and Microbiomes
- Vol. 8 (1) , 1-15
Microbiome-derived antimicrobial peptides offer therapeutic solutions for the treatment of Pseudomonas aeruginosa infections
Microbiomes are rife for biotechnological exploitation, particularly the rumen microbiome, due to their complexicity and diversity. In this study, antimicrobial peptides (AMPs) from the rumen microbiome (Lynronne 1, 2, 3 and P15s) were assessed for their therapeutic potential against seven clinical strains of Pseudomonas aeruginosa. All AMPs exhibited antimicrobial activity against all strains, with minimum inhibitory concentrations (MICs) ranging from 4–512 µg/mL. Time-kill kinetics of all AMPs at 3× MIC values against strains PAO1 and LES431 showed complete kill within 10 min to 4 h, although P15s was not bactericidal against PAO1. All AMPs significantly inhibited biofilm formation by strains PAO1 and LES431, and induction of resistance assays showed no decrease in activity against these strains. AMP cytotoxicity against human lung cells was also minimal. In terms of mechanism of action, the AMPs showed affinity towards PAO1 and LES431 bacterial membrane lipids, efficiently permeabilising the P. aeruginosa membrane. Transcriptome and metabolome analysis revealed increased catalytic activity at the cell membrane and promotion of β-oxidation of fatty acids. Finally, tests performed with the Galleria mellonella infection model showed that Lynronne 1 and 2 were efficacious in vivo, with a 100% survival rate following treatment at 32 mg/kg and 128 mg/kg, respectively. This study illustrates the therapeutic potential of microbiome-derived AMPs against P. aeruginosa infections.
- 29 August 2022
- Published by Springer Nature in npj Biofilms and Microbiomes
- Vol. 8 (1) , 1-15
Open AccessMicrobiome-derived antimicrobial peptides offer therapeutic solutions for the treatment of Pseudomonas aeruginosa infections
Microbiomes are rife for biotechnological exploitation, particularly the rumen microbiome, due to their complexicity and diversity. In this study, antimicrobial peptides (AMPs) from the rumen microbiome (Lynronne 1, 2, 3 and P15s) were assessed for their therapeutic potential against seven clinical strains of Pseudomonas aeruginosa. All AMPs exhibited antimicrobial activity against all strains, with minimum inhibitory concentrations (MICs) ranging from 4–512 µg/mL. Time-kill kinetics of all AMPs at 3× MIC values against strains PAO1 and LES431 showed complete kill within 10 min to 4 h, although P15s was not bactericidal against PAO1. All AMPs significantly inhibited biofilm formation by strains PAO1 and LES431, and induction of resistance assays showed no decrease in activity against these strains. AMP cytotoxicity against human lung cells was also minimal. In terms of mechanism of action, the AMPs showed affinity towards PAO1 and LES431 bacterial membrane lipids, efficiently permeabilising the P. aeruginosa membrane. Transcriptome and metabolome analysis revealed increased catalytic activity at the cell membrane and promotion of β-oxidation of fatty acids. Finally, tests performed with the Galleria mellonella infection model showed that Lynronne 1 and 2 were efficacious in vivo, with a 100% survival rate following treatment at 32 mg/kg and 128 mg/kg, respectively. This study illustrates the therapeutic potential of microbiome-derived AMPs against P. aeruginosa infections.